Abstract 2299
Background
The optimal chemotherapy regimen for concurrent chemoradiation in locally advanced non-small cell lung cancer (NSCLC) remains unclear. Cisplatin-etoposide regimen related toxicity is high, weekly regimens have been investigating. We aimed to compare the efficacy and safety of different concurrent chemotherapy regimens in the context.
Methods
A total of 225 patients with locally advanced, unresectable stage III NSCLC included. Patients who treated with weekly docetaxel-platin (DP), paclitaxel-platin (PP) and standard dose etoposide-platin (EP) chemotherapy regimens were selected and divided to groups for the comparison of toxicity, response rate, progression free survival (PFS) and overall survival (OS) rates.
Results
There was statistically significant difference between overall response rate of each treatment groups (DP: 96,1%, PP: 94% and EP:76.7%, p < 0.001). The median PFS rate of patients who treated with DP, PP and EP was 16, 15 and 13.3 months, respectively (p = 0.435). The median OS of patients treated with DP, PP and EP was 19.2, 29.7 and 28.3 months, respectively (p = 0.092). The rates of adverse events such as nausea, vomiting, neuropathy and anaphylaxis was similar. Grade 1-2 mucositis or esophagitis, anemia, pneumonitis were significantly higher in PP group than other groups. However, hematologic toxicities were higher in the EP group than other groups.Table:
1464P
Patients characteristics | ||||
---|---|---|---|---|
DP (N = 102) N(%) | PP (N = 50) N(%) | EP (N = 73) N(%) | P | |
Median age | 61 | 64 | 58 | 0.038 |
Gender Male | 93(91.2) | 48(96) | 64(87.7) | 0.28 |
Histopathology Squamous cell | 53(52) | 31(62) | 43(58.9) | <0.001 |
Stage IIIB-IIIC | 65(63.7) | 31(62) | 41(56.2) | 0.59 |
Conclusions
When the weekly chemotherapy regimens were compared with the standard dose, our study demonstrated similar survival rates but better treatment response rates. Adverse events and toxicity rates were different and depending on the type of chemotherapy regimen used.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Abdurrahman Işıkdogan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4526 - Long-term outcome of neoadjuvant tyrosine kinase inhibitors (TKI) in locally advanced dermatofibrosarcoma protuberans (DFSP)
Presenter: Jessica Beaziz
Session: Poster Display session 1
Resources:
Abstract
1214 - Neo-adjuvant (NA) Imatinib for gastrointestinal stromal tumours (GISTs): What is the optimal length of treatment?
Presenter: Tom Wilson
Session: Poster Display session 1
Resources:
Abstract
2690 - Gastrointestinal Stromal Tumours (GIST) in adolescents and young adults (AYA)
Presenter: Nikki Ijzerman
Session: Poster Display session 1
Resources:
Abstract
4558 - Radiomics improves response evaluation for desmoid tumors treated with chemotherapy
Presenter: Amandine Crombe
Session: Poster Display session 1
Resources:
Abstract
2751 - Radiomics of gastrointestinal stromal tumors; risk classification based on computed tomography images – a pilot study
Presenter: Milea Timbergen
Session: Poster Display session 1
Resources:
Abstract
2737 - Differentiating well-differentiated liposarcomas from lipomas using a radiomics approach
Presenter: Melissa Vos
Session: Poster Display session 1
Resources:
Abstract
1282 - The immune landscape of chondrosarcoma reveals an anti inflammatory environment
Presenter: Iseulys Richert
Session: Poster Display session 1
Resources:
Abstract
1572 - Impact of Immunotherapy and Targeted Therapy on Tumor Growth Rate in Sarcoma
Presenter: Esmail Al-ezzi
Session: Poster Display session 1
Resources:
Abstract
3414 - DNA methylation profiles of angiosarcoma subtypes.
Presenter: Marije Weidema
Session: Poster Display session 1
Resources:
Abstract
3411 - Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As and BTN3A1 in patients with metastatic gastrointestinal stromal tumors (mGISTs)
Presenter: Daniele Fanale
Session: Poster Display session 1
Resources:
Abstract